S. Deva

发表

Histamine type 2 receptor antagonists as adjuvant treatment for resected colorectal cancer.

S. Deva, M. Jameson, 2012, The Cochrane database of systematic reviews.

Dose-intense capecitabine, oxaliplatin and bevacizumab as first line treatment for metastatic, unresectable colorectal cancer: a multi-centre phase II study

V. Hinder, M. Findlay, K. Sharples, 2014, BMC Cancer.

The combination of gene hyperamplification and PD-L1 expression as a biomarker for the clinical benefit of tislelizumab in gastric/gastroesophageal junction adenocarcinoma

Yangguang Shi, Y. Chao, Zhihao Lu, 2022, Gastric Cancer.

Everolimus and zoledronic acid in patients with renal cell carcinoma with bone metastases: a randomized first-line phase II trial.

A. Grey, V. Hinder, P. Fong, 2015, Clinical genitourinary cancer.

The effects of sorafenib and sunitinib on bone turnover markers in patients with bone metastases from renal cell carcinoma.

J. Knox, V. Hinder, R. Broom, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The combination of gene hyperamplification and PD-L1 expression as a biomarker for the clinical benefit of tislelizumab in gastric/gastroesophageal junction adenocarcinoma

Yangguang Shi, Y. Chao, Zhirong Shen, 2022, Gastric Cancer.

Oral paclitaxel with encequidar compared to intravenous paclitaxel in patients with advanced cancer: A randomised crossover pharmacokinetic study

T. Chao, D. Cutler, H. Prenen, 2020, British journal of clinical pharmacology.

Real‐world outcomes of cisplatin, capecitabine, and gemcitabine with either epirubicin (PEXG) or docetaxel (PDXG) as first‐line palliative treatment in metastatic or unresectable locally advanced pancreatic adenocarcinoma

M. Findlay, S. Deva, N. Waldron, 2022, Asia-Pacific journal of clinical oncology.

Intralesional SD-101 in Combination with Pembrolizumab in Anti-PD-1 Treatment-Naïve Head and Neck Squamous Cell Carcinoma: Results from a Multicenter, Phase II Trial

G. Daniels, O. Guntinas-Lichius, M. Milhem, 2021, Clinical cancer research : an official journal of the American Association for Cancer Research.

Mortality within 30 days of systemic anticancer therapy at a tertiary cancer centre: assessing the safety and quality of clinical care.

Michelle K Wilson, M. Findlay, S. Deva, 2017, The New Zealand medical journal.

Phase IA/IB study of single-agent tislelizumab, an investigational anti-PD-1 antibody, in solid tumors

J. Desai, K. Rau, M. Friedlander, 2020, Journal for immunotherapy of cancer.

An extended phase Ib study of epertinib, an orally active reversible dual EGFR/HER2 tyrosine kinase inhibitor, in patients with solid tumours.

R. Plummer, M. Toulmonde, A. Italiano, 2018, European journal of cancer.

Cardiac Troponin I and T in Checkpoint Inhibitor-associated Myositis and Myocarditis.

S. Deva, Edmond Ang, G. Rivalland, 2021, Journal of immunotherapy.

528 Intratumoural treatment with LTX-, an oncolytic peptide immunotherapy, in patients with advanced metastatic disease induces CD8 effector cells and regression in some injected tumours

J. Spicer, A. Awada, P. Barthélémy, 2015 .

Dose-intense capecitabine, oxaliplatin and bevacizumab as first line treatment for metastatic, unresectable colorectal cancer: a multi-centre phase II study

V. Hinder, M. Findlay, K. Sharples, 2014, BMC Cancer.

Response to BRAF-targeted Therapy Is Enhanced by Cotargeting VEGFRs or WNT/β-Catenin Signaling in BRAF-mutant Colorectal Cancer Models

C. Buchanan, P. Shepherd, S. Deva, 2022, Molecular cancer therapeutics.

A phase Ia/Ib trial of tislelizumab, an anti-PD-1 antibody (ab), in patients (pts) with advanced solid tumors

J. Desai, K. Rau, M. Friedlander, 2018, Annals of Oncology.

387PPreliminary results from subsets of patients (pts) with advanced gastric cancer (GC) and esophageal carcinoma (EC) in a dose-escalation/expansion study of BGB-A317, an anti-PD-1 monoclonal antibody (mAb)

J. Desai, M. Millward, Y. Chao, 2017 .

Phase 1b/2, open label, multicenter study of intratumoral SD-101 in combination with pembrolizumab in anti-PD-1 treatment naïve patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC).

R. Janssen, G. Daniels, O. Guntinas-Lichius, 2019, Journal of Clinical Oncology.

Response to BRAF-targeted Therapy Is Enhanced by Cotargeting VEGFRs or WNT/β-Catenin Signaling in BRAF-mutant Colorectal Cancer Models

Khanh B. Tran, C. Buchanan, P. Shepherd, 2022, Molecular cancer therapeutics.

Abstract P4-14-26: Phase I expansion of S-222611, a reversible inhibitor of EGFR and HER2, in advanced solid tumors, including HER2-positive breast cancer patients with brain metastases

R. Plummer, E. Frenkel, A. Italiano, 2016 .

First-line durvalumab + monalizumab, mFOLFOX6, and bevacizumab or cetuximab for metastatic microsatellite-stable colorectal cancer (MSS-CRC).

G. Curigliano, N. Segal, Z. Wainberg, 2020 .

P-163 Real-world outcomes of cisplatin, capecitabine and gemcitabine with either epirubicin (PEXG) or docetaxel (PDXG) as first-line palliative treatment in metastatic or unresectable locally advanced pancreatic adenocarcinoma

M. Findlay, S. Deva, G. Rivalland, 2021, Annals of Oncology.

Oral PD-L1 inhibitor GS-4224 selectively engages PD-L1 high cells and elicits pharmacodynamic responses in patients with advanced solid tumors

L. Lad, D. Thai, S. Deva, 2024, Journal for ImmunoTherapy of Cancer.

List of Best of the Best Oral Abstracts

A. Grey, P. Fong, M. Findlay, 2012 .

Invited Presentations and Oral Abstracts

P. Fong, K. Sharples, M. Findlay, 2012 .